Sarepta Therapeutics: Safety Update on ELEVIDYS in Non-Ambulatory Individuals Living with Duchenne

Sarepta Therapeutics recently joined PPMD for a community webinar to share details from the company’s recent safety update on ELEVIDYS and discuss steps the company is proactively taking in response to the second reported case of acute liver failure in a non-ambulatory patient resulting in death following treatment with ELEVIDYS. Following the presentation, Sarepta answered questions from the community.